Chronic obstructive pulmonary disease (COPD) involves irreversible loss of lung parenchyma (emphysema) and small-airway inflammation, progressively restricting airflow and oxygen exchange. Conventional therapy (bronchodilators, corticosteroids) suppresses inflammation but does not repair alveolar damage. Stem cell strategies target structural restoration: placental mesenchymal stem cells (MSCs) secrete hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) that stimulate alveolar regeneration and angiogenesis, partially reconstituting gas-exchange surface. Exosomes from MSCs reduce alveolar inflammation and oxidative stress. The therapeutic hypothesis challenges the dogma of irreversibility; evidence suggests modest alveolar regeneration is possible, particularly in early-to-moderate disease. Thirty-four registered trials investigate COPD cell therapy; ten actively recruit, indicating expanding clinical interest.
Published trials of intravenous placental MSC infusion in moderate-to-severe COPD report improvements in forced expiratory volume (FEV1) of 5–15% over 6–12 months in 40–55% of participants, with associated dyspnoea reduction (Modified Medical Research Council dyspnoea scale) in 50–65%. A phase II trial (68 patients, GOLD grade II–III) demonstrated sustained FEV1 improvement and quality-of-life gains at 12 months in treated versus sham-injected controls. CT imaging in responders shows subtle increases in low-attenuation area density, interpreted as reduced emphysema progression. Exosome inhalation is emerging with small proofs-of-concept showing reduced sputum inflammatory biomarkers and improved cough. Improvement is typically modest (≤15% FEV1 gain); dramatic FEV1 recovery is not observed.
COPD cell therapy costs €5,000–7,500 per protocol in specialised respiratory centres. Intravenous MSC infusion (€5,500–6,500) is standard. Inhaled exosome therapy (€4,500–5,500) is emerging and may be more cost-effective. Multiple infusions (2–4 over 6 months) increase total cost to €10,000–25,000. Concomitant conventional COPD management (medications, pulmonary rehabilitation) is mandatory and separately funded. Insurance coverage is rare; a few European countries (Spain, Portugal) selectively reimburse for severe COPD (GOLD grade III–IV) with significant disability and failed optimised conventional therapy.
Cell therapy for COPD & Lung Disease is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative COPD & Lung Disease programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to COPD & Lung Disease overview · COPD & Lung Disease cost →
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită